Skip to main content
SpringerLink
Log in

Prostate Cancer

  • Chapter
  • First Online:
Oncology in the Precision Medicine Era

Abstract

Prostate cancer is the most common cancer (besides skin cancer) diagnosed in men, yet from the time of screening to diagnosis and to treatment, the care paradigm can benefit from precision medicine. There is clearly a need to confidently avoid treatment for cancers that are slow growing, provide the optimal treatment to eliminate cancer primarily, and control aggressive disease using personalized treatment goals and regimens. We are moving beyond a prostate-specific antigen (PSA)-driven care model world to where other forms of assays provide better risk estimation and the decision process with patient and doctor is more data-driven. While the treatment of metastatic prostate cancer remains challenging, novel agents continue to be developed, and precision medicine may provide the information we need regarding which agents to use and in what time frame. Additional studies are still needed to improve the effectiveness of precision medicine in prostate cancer, but the movement is fundamental to improving our knowledge and ability to treat this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442. Epub 2018 Jan 4.

    Article  PubMed  Google Scholar 

  2. Wise AM, Stamey TA, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264–9.

    Article  PubMed  Google Scholar 

  3. Carroll PR. USPTF prostate cancer screening recommendations-a step in the right direction. JAMA Surg. 2018;153(8):701. https://doi.org/10.1001/jamasurg.2018.1283.

    Article  PubMed  Google Scholar 

  4. Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, et al.; Nordic Twin Study of Cancer (NorTwinCan) Collaboration. Familial risk and heritability of cancer among Twins in Nordic Countries. JAMA. 2016;315(1):68–76. https://doi.org/10.1001/jama.2015.17703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16(5S):620–3. https://doi.org/10.6004/jnccn.2018.0036.

    Article  PubMed  Google Scholar 

  6. Schumacher FR, Al Olama AA, Berndt SI. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928. https://doi.org/10.1038/s41588-018-0142-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Russo GI, Regis F, Castelli T, Favilla V, Privitera S, Giardina R, Cimino S, Morgia G. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-Kallikrein panel score in predicting overall and high-grade prostate cancer. Clin Genitourin Cancer. 2017;15(4):429–439.e1. https://doi.org/10.1016/j.clgc.2016.12.022. Epub 2016 Dec 30.

    Article  PubMed  Google Scholar 

  8. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, et al.; Canary Prostate Active Surveillance Study Investigators. Evaluating the four Kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer in men in the Canary Prostate Active Surveillance Study. Eur Urol. 2017;72(3):448–454. https://doi.org/10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23.

    Article  CAS  PubMed  Google Scholar 

  9. de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy Naïve Men. J Urol. 2015;194(1):65–72. https://doi.org/10.1016/j.juro.2015.01.091. Epub 2015 Jan 28.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54(5):1081–8.

    Article  PubMed  Google Scholar 

  11. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32(36):4066–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Seisen T, Rouprêt M, Brault D, Léon P, Cancel-Tassin G, Compérat E, et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate. 2015;75(1):103–11.

    Article  PubMed  Google Scholar 

  13. Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70(5):740–8. https://doi.org/10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

    Article  CAS  PubMed  Google Scholar 

  14. McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2(7):882–9. https://doi.org/10.1001/jamaoncol.2016.0097.

    Article  PubMed  Google Scholar 

  15. Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013;189(3):1110–6. https://doi.org/10.1016/j.juro.2012.08.219.. Epub 2012 Oct 8

    Article  PubMed  Google Scholar 

  16. Reichard CA, Stephenson AJ, Klein EA. Applying precision medicine to the active surveillance of prostate cancer. Cancer. 2015;121(19):3403–11. https://doi.org/10.1002/cncr.29496. Epub 2015 Jul 6.

    Article  PubMed  Google Scholar 

  17. Klein EA, Haddad Z, Yousefi K, et al. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology. 2016;90:148–52. https://doi.org/10.1016/j.urology.2016.01.012.

    Article  PubMed  Google Scholar 

  18. Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, et al. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J Clin Oncol. 2017;35(18):1991–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol. 2018;36(6):581–90.

    Article  PubMed  Google Scholar 

  20. Blume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res. 2015;21:2591–600. https://doi.org/10.1158/1078-0432.CCR-14-2603.

    Article  CAS  PubMed  Google Scholar 

  21. Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113(3):382–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al., Transatlantic Prostate Group. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(1):107–15. https://doi.org/10.1016/j.eururo.2014.11.038. Epub 2014 Dec 4. Review.

    Article  PubMed  Google Scholar 

  24. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:848–53. https://doi.org/10.1016/j.ijrobp.2013.04.043.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68(1):123–31. https://doi.org/10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.

    Article  PubMed  Google Scholar 

  26. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al.; PRECISION Study Group Collaborators. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–1777. https://doi.org/10.1056/NEJMoa1801993. Epub 2018 Mar 18.

    Article  PubMed  Google Scholar 

  27. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017:1. https://doi.org/10.1200/PO.17.00029. Epub 2017 May 31.

    Article  Google Scholar 

  28. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018;124(5):1008–15. https://doi.org/10.1002/cncr.31173. Epub 2017 Dec 19.

    Article  CAS  PubMed  Google Scholar 

  30. Liu W, Yin B, Wang X, Yu P, Duan X, Liu C, Wang B, Tao Z. Circulating tumor cells in prostate cancer: precision diagnosis and therapy. Oncol Lett. 2017;14(2):1223–32. https://doi.org/10.3892/ol.2017.6332. Epub 2017 Jun 7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zheng Y, Zhang C, Wu J, Cheng G, Yang H, Hua L, Wang Z. Prognostic value of circulating tumor cells in castration resistant prostate cancer: a meta-analysis. Urol J. 2016;13(6):2881–8.

    PubMed  Google Scholar 

  32. Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017;16(1):80. https://doi.org/10.1186/s12943-017-0644-5.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25. https://doi.org/10.1016/j.cell.2015.10.025.

    Article  Google Scholar 

  34. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28. https://doi.org/10.1016/j.cell.2015.05.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2018. pii: S0302–2838(18)30246-X.; https://doi.org/10.1016/j.eururo.2018.03.028.

    Article  PubMed  Google Scholar 

  36. Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. TherAdv Med Oncol. 2017;9(8):565–73. https://doi.org/10.1177/1758834017719215. Epub 2017 Jul 5.

    Article  CAS  Google Scholar 

  37. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res. 2007;35(8):2767–76. Epub 2007 Apr 10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19(1):76–86. https://doi.org/10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

    Article  CAS  PubMed  Google Scholar 

  39. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56. https://doi.org/10.1200/JCO.2016.70.1961. Epub 2017 Apr 6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, et al. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. Eur Urol. 2018;73(5):727–35. https://doi.org/10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1.

    Article  CAS  PubMed  Google Scholar 

  41. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.

    Article  CAS  PubMed  Google Scholar 

  42. Arora K, Barbieri CE. Molecular subtypes of prostate cancer. Curr Oncol Rep. 2018;20(8):58. https://doi.org/10.1007/s11912-018-0707-9. Review.

    Article  CAS  PubMed  Google Scholar 

  43. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017:1. https://doi.org/10.1200/PO.17.00029. Epub 2017 May 31.

    Article  Google Scholar 

  44. Rubin MA, Demichelis F. The genomics of prostate cancer: emerging understanding with technologic advances. Mod Pathol. 2018;31(S1):S1–11. https://doi.org/10.1038/modpathol.2017.166.

    Article  PubMed  Google Scholar 

  45. Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, et al. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investig New Drugs. 2018;36:1060. https://doi.org/10.1007/s10637-018-0625-6.

    Article  CAS  Google Scholar 

  46. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol. 2016;69(6):992–5.

    Article  CAS  PubMed  Google Scholar 

  47. Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP inhibitors in prostate cancer. Curr Treat Options in Oncol. 2017;18(6):37. https://doi.org/10.1007/s11864-017-0480-2. Review.

    Article  Google Scholar 

  48. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19(5):664–78. https://doi.org/10.1016/j.ccr.2011.04.010. Erratum in: Cancer Cell. 2013 Apr 15;23(4):557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol. 2017;28(7):1495–507. https://doi.org/10.1093/annonc/mdx165.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018;9(47):28561–71. https://doi.org/10.18632/oncotarget.25564. eCollection 2018 Jun 19.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29:1807. https://doi.org/10.1093/annonc/mdy232.

    Article  CAS  PubMed  Google Scholar 

  53. Sant GR, Knopf KB, Albala DM. Live-single-cell phenotypic cancer biomarkers-future role in precision oncology? NPJ Precis Oncol. 2017;1(1):21. https://doi.org/10.1038/s41698-017-0025-y. eCollection 2017.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA

    Bertram Yuh

  2. Department of Cancer Biology, City of Hope National Medical Center, Duarte, CA, USA

    Zijie Sun

Authors
  1. Bertram Yuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zijie Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zijie Sun .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA

    Ravi Salgia

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yuh, B., Sun, Z. (2020). Prostate Cancer. In: Salgia, R. (eds) Oncology in the Precision Medicine Era. Springer, Cham. https://doi.org/10.1007/978-3-030-31471-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31471-2_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-31470-5

  • Online ISBN: 978-3-030-31471-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation